Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential Treatments-Reference-Cited by-同舟云学术

Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential Treatments

Published:2022-08-02 Issue:1 Volume:107 Page:156-161
ISSN:0041-1337
Container-title:Transplantation
language:en
Short-container-title:

Author:

Tovoli Francesco,Pallotta Dante Pio,Sansone Vito,Iavarone Massimo,De Giorgio Massimo,Ielasi Luca,Di Costanzo Giovan Giuseppe,Giuffrida Paolo,Sacco Rodolfo,Pressiani Tiziana,Di Donato Maria Francesca,Trevisani Franco,Fagiuoli Stefano,Piscaglia Fabio,Granito Alessandro

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Transplantation

Reference41 articles.

1. Experience with early sorafenib treatment with mTOR Inhibitors in hepatocellular carcinoma recurring after liver transplantation.;Invernizzi;Transplantation,2020

2. Immune checkpoint inhibitors in organ transplant patients.;Kittai;J Immunother,2017

3. Use of checkpoint inhibitors in liver transplant recipients.;Munker;United European Gastroenterol J,2018

4. Sorafenib in advanced hepatocellular carcinoma.;Llovet;N Engl J Med,2008

5. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.;Cheng;Lancet Oncol,2009

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic Treatment of Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Multicenter Trial;Cancers;2024-07-03

2. Pushing the limits of treatment for hepatocellular carcinoma;Current Opinion in Organ Transplantation;2023-11-30

3. Recent advances in recurrent hepatocellular carcinoma therapy;World Journal of Hepatology;2023-04-27

4. Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma;Cancers;2023-02-28

5. TKIs in combination with immunotherapy for hepatocellular carcinoma;Expert Review of Anticancer Therapy;2023-02-26